Bispecific T cell engagers kill resistant cells during KRAS-G12C blockade therapy

The covalent KRAS-G12C inhibitors (G12Ci) are rapidly changing the treatment landscape for advanced non-small cell lung cancer, but drug resistance remains a clinical challenge. Two recent studies have developed bispecific T cell engagers that form a link between T cells and tumor cells to selective...

Full description

Bibliographic Details
Published in:	OncoImmunology
Main Authors:	Xinxin Song, Zhuan Zhou, Rui Kang, Daolin Tang
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2022-12-01
Subjects:	KRAS-G12C bispecific T cell engagers
Online Access:	https://www.tandfonline.com/doi/10.1080/2162402X.2022.2141978

Similar Items

Potent antitumor activity of a bispecific T-cell engager antibody targeting the intracellular antigen KRAS G12V
by: Changchang Lu, et al.
Published: (2024-05-01)

Kristen rat sarcoma virus (KRAS) G12F‐positive non‐small cell lung cancer mimicking KRAS G12C positivity: A case report
by: Issei Oi, et al.
Published: (2024-01-01)

KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?
by: Sahar F. Bannoura, et al.
Published: (2022-11-01)

An Engineered Soluble Single‐Chain TCR Engager for KRAS‐G12V Specific Tumor Immunotherapy
by: Keke Ma, et al.
Published: (2025-08-01)

An In Vivo Inflammatory Loop Potentiates KRAS Blockade
by: Kristina A. M. Arendt, et al.
Published: (2022-03-01)

<i>A First-Class Degrader Candidate Targeting Both</i> KRAS G12D and G12V Mediated by CANDDY Technology Independent of Ubiquitination
by: Etsuko Miyamoto-Sato, et al.
Published: (2023-07-01)

KRAS G12C inhibitor combination therapies: current evidence and challenge
by: Hirotaka Miyashita, et al.
Published: (2024-05-01)

Study of the blood–brain barrier-penetrating KRAS G12C inhibitor JMKX1899 in KRAS G12C-mutated NSCLC with brain metastases
by: Danming He, et al.
Published: (2026-06-01)

Efficacy of immune checkpoint inhibitors in patients with KRAS-mutant advanced non-small cell lung cancer: A retrospective analysis
by: Gu Xiaodong, et al.
Published: (2023-03-01)

Integrative proteomic characterization of human lung adenocarcinoma with KRAS G12 mutations reveals molecular pathogenesis
by: Xinyu Shi, et al.
Published: (2026-06-01)

Combination of farnesyl-transferase inhibition with KRAS G12D targeting breaks down therapeutic resistance in pancreatic cancer
by: Eszter Molnár, et al.
Published: (2024-12-01)

Dissecting the Clinical Characteristics and Treatment Outcomes Correlates of KRAS G12C-Mutated Non-Small Cell Lung Cancer
by: Jing Y, et al.
Published: (2024-10-01)

Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients
by: Si-Yang Liu, et al.
Published: (2020-06-01)

Design, synthesis, and evaluation of purine and pyrimidine-based KRAS G12D inhibitors: Towards potential anticancer therapy
by: So-Youn Park, et al.
Published: (2024-04-01)

Clinicopathologic features and KRAS mutation incidence of gastric carcinomas
by: Didar Gürsoy, et al.
Published: (2022-01-01)

Bispecific T-Cell Engagers and Chimeric Antigen Receptor T-Cell Therapies in Glioblastoma: An Update
by: Roa Alsajjan, et al.
Published: (2023-09-01)

KRAS-mutated non-small cell lung cancer: new therapy strategies
by: K. K. Laktionov, et al.
Published: (2024-05-01)

TEAD Inhibitors Sensitize KRAS<sup>G12C</sup> Inhibitors via Dual Cell Cycle Arrest in KRAS<sup>G12C</sup>-Mutant NSCLC
by: Salvina Laura Tammaccaro, et al.
Published: (2023-04-01)

Dual inhibition of GTP-bound KRAS and mTOR in lung adenocarcinoma and squamous cell carcinoma harboring KRAS G12C
by: Masaoki Ito, et al.
Published: (2025-05-01)

Elucidating heavy/light chain pairing preferences to facilitate the assembly of bispecific IgG in single cells
by: Kamal Kishore Joshi, et al.
Published: (2019-10-01)

KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer
by: Emerik Osterlund, et al.
Published: (2022-02-01)

New exploration of KRASG12D inhibitors and the mechanisms of resistance
by: Ying Li, et al.
Published: (2025-03-01)

Concomitant Mutations G12D and G13D on the Exon 2 of the KRAS Gene: Two Cases of Women with Colon Adenocarcinoma
by: Elena De Falco, et al.
Published: (2021-04-01)

Editorial: KRAS in stage IV non-small cell lung cancer
by: Anneloes L. Noordhof, et al.
Published: (2025-03-01)

Mapping the Interactome of KRAS and Its G12C/D/V Mutants by Integrating TurboID Proximity Labeling with Quantitative Proteomics
by: Jiangwei Song, et al.
Published: (2025-04-01)

Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer
by: Tian Huan, et al.
Published: (2023-08-01)

Covalent inhibitor targets KRasG12C: A new paradigm for drugging the undruggable and challenges ahead
by: Hui-yu Li, et al.
Published: (2023-03-01)

Recombinant KRAS G12D Protein Vaccines Elicit Significant Anti-Tumor Effects in Mouse CT26 Tumor Models
by: Yuhua Wan, et al.
Published: (2020-08-01)

Half-Life Extended Nanobody-Based CD38-Specific Bispecific Killercell Engagers Induce Killing of Multiple Myeloma Cells
by: Julia Hambach, et al.
Published: (2022-05-01)

De Novo KRAS G12C–Mutant SCLC: A Case Report
by: Meridith L. Balbach, BS, et al.
Published: (2022-05-01)

Brief Report: Real-World Efficacy and Safety of Sotorasib in U.S. Veterans with KRAS G12C-Mutated NSCLC
by: Katherine I. Zhou, MD, PhD, et al.
Published: (2024-05-01)

Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC
by: Parneet K. Cheema, et al.
Published: (2023-07-01)

Evaluation of Bispecific T-Cell Engagers Targeting Murine Cytomegalovirus
by: Hanna Menschikowski, et al.
Published: (2024-05-01)

A Novel Tetravalent Bispecific Immune Cell Engager Activates Natural Killer Cells to Kill Cancer Cells without Mediating Fratricide
by: Ge Yang, et al.
Published: (2024-09-01)

KRAS G12C mutation in NSCLC in a small genetic center: insights into sotorasib therapy response potential
by: Metin Eser, et al.
Published: (2024-11-01)

Identification of Dietary Bioflavonoids as Potential Inhibitors against KRAS G12D Mutant—Novel Insights from Computer-Aided Drug Discovery
by: Prasanna Srinivasan Ramalingam, et al.
Published: (2023-03-01)

Structural and functional characterization of IgG- and non-IgG-based T-cell-engaging bispecific antibodies
by: Nishant Mohan, et al.
Published: (2024-05-01)

Therapeutic Bispecific T-Cell Engager Antibody Targeting the Transferrin Receptor
by: Mingpeng Fu, et al.
Published: (2019-06-01)

Prognostic Role of <i>KRAS G12C</i> Mutation in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
by: Durgesh Wankhede, et al.
Published: (2023-09-01)

KEAP1 mutations as key crucial prognostic biomarkers for resistance to KRAS-G12C inhibitors
by: Linyan Tian, et al.
Published: (2025-01-01)